1240304-44-2

Upstream product

• 1240304-42-0 (1S)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-1-[2-hydroxy-4-(propan-2-yl)phenyl]-D-glucitol 
• 1240304-37-3 (1S)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-1-[2-(benzyloxy)-4-(propan-2-yl)phenyl]-D-glucitol 
• 1240304-35-1 2-(benzyloxy)-1-iodo-4-(propan-2-yl)benzene 
• 618-45-1 3-isopropylhydroxybenzene 
• 1017608-23-9 2-iodo-5-(propan-2-yl)phenol 

Downstream Products

• 1240304-48-6 C₂₃H₂₉BrO₇ 
• 1240304-31-7 (1S)-2,3,4,6-tetra-O-acetyl-1-[2-(acetyloxy)-5-[(4-bromo-2-methylphenyl)methyl]-4-(propan-2-yl)phenyl]-1,5-anhydro-D-glucitol 
• 1240304-46-4 (1S)-1,5-anhydro-1-{5-bromo-4-(propan-2-yl)-2-[(trimethylsilyl)oxy]phenyl}-2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucitol 
• 1240304-51-1 C₃₃H₃₉BrO₁₂ 
• 1369430-79-4 C₃₉H₄₈O₁₃ 
• 1369430-81-8 C₃₇H₅₅N₃O₈ 
• 1369430-92-1 C₃₇H₅₅N₃O₈ 
• 1369430-76-1 C₄₃H₅₅NO₁₄ 
• 1369430-91-0 C₄₇H₆₅N₃O₁₃ 
• 1369430-80-7 C₄₇H₆₅N₃O₁₃ 
• 1369430-89-6 C₅₀H₆₉N₃O₁₃ 
• 1369430-93-2 C₅₂H₇₃N₃O₁₅ 

Relevant academic research and scientific papers

Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment

A new series of C-phenyl D-glucitol derivatives was designed and synthesized, and their SGLT1 inhibitory potency and absorbability were evaluated. We also investigated whether kidney drug retention could be avoided by creating molecules with different excretion pathways. To achieve a class of molecules with low absorption and that were excreted in bile, optimized synthesis was performed to bring the ClogP value and the topological polar surface area to within the appropriate ranges. Compounds 34d and 34j were poorly absorbed, but the absorbed compounds were mainly excreted in bile. Thus, smaller amounts of persistent residue in the kidneys were observed. Since 34d exerted a glucose-lowering effect at a dose of 0.3 mg/kg (p.o.) in SD rats, this compound (SGL5213) could be a clinical candidate for the treatment of type 2 diabetes.

4 -ISOPROPYLPHENYL GLUCITOL COMPOUNDS AS SGLTL INHIBITORS

The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: [Chem. 1] wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group(s), etc., and R4 represents a hydrogen atom, etc.